Anti-tumor activity of Titanocene Y in xenografted Caki-1 tumors in mice

Fichtner, I., Pampillon, C., Sweeney, N.J., Strohfeldt, K. and Tacke, M. (2006) Anti-tumor activity of Titanocene Y in xenografted Caki-1 tumors in mice. Anti-Cancer Drugs, 17 (3). pp. 333-336. ISSN 0959-4973

Abstract/Summary

The benzyl-substituted unbridged titanocene bis-[(p-methoxybenzyl)cyclopentadienyl] titanium(IV) dichloride (Titanocene Y) was tested in vitro against human renal cancer cells (Caki-1), in which it showed an IC50 value of 36 x 10(-6) mol/l. Titanocene Y was then given in vivo in doses of 10, 20, 30, 40 and 50 mg/kg on 5 consecutive days to Caki-1-bearing mice, and it showed concentration-dependent and statistically significant tumor growth reduction with respect to a solvent-treated control cohort. The maximum tolerable dose of Titanocene Y was determined to be 40 mg/kg and it showed significantly better tumor volume growth reduction than cisplatin given at a dose of 2 mg/kg. This superior activity of Titanocene Y with respect to cisplatin will hopefully lead to clinical tests against metastatic renal cell cancer in the near future.